Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia’s Focal Adhesion Kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer. HIGHLIGHTS The US FDA has granted Fast Track Designation…
How to best invest in silver is a thought on many investors’ minds. Silver has long been an attractive…
The US Federal Reserve reduced its benchmark interest rate for the first time in four years on Wednesday (September…
Investor Insight An innovative technology that promises positive economics place Altech Batteries in a compelling position to take advantage…
Falcon Gold Corp.(TSXV:FG)(3FA:GR)(OTCQB:FGLDF); (‘Falcon’ or the ‘Company’) is pleased to report drilling has commenced at our Great Burnt Copper…
Wheaton Precious Metals ( TSX:WPM,NYSE:WPM)announced the launch of the Future of Mining Challenge, a global competition aimed at advancing…
NioCorp Developments (NASDAQ:NB) said on Wednesday (September 18) that it will discuss its plans for producing and potentially recycling…
The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the…
Sarama Resources Ltd. (“Sarama” or the “Company”) (ASX:SRR, TSX- V:SWA) is pleased to report that on 18 September 2024,…